Glenmark USA acquires and launches Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose…
Glenmark acquired the ANDA for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials from Aspen Pharma USA
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Glenmark Pharmaceuticals
Glenmark announces launch of Epinephrine Injection USP, 10 mg/10 mL (1 mg/mL) multiple-dose vial
The launch is eligible for 180 days of CGT exclusivity under the FD&C Act
Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution in the US
Latanoprost Ophthalmic Solution, 0.005 per cent introduced as a bioequivalent alternative to Xalatan
Glenmark launches Clindamycin Phosphate Foam
The new product targets a market worth $5.8 million
Glenmark secures MHRA approval to launch Winlevi in the UK
Winlevi, licensed from Cosmo Pharmaceuticals, introduces a new topical approach to acne treatment
Glenmark launches Lacosamide Oral Solution, bioequivalent to Vimpat
Lacosamide Oral Solution, 10 mg/mL, enters the U.S. market with an annual market size of $57 million
Glenmark gets ANDA approval for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the US by Glenmark Therapeutics, US
Glenmark ranks No.1 in dermatologist prescriptions for protective emollients and derma therapy:…
Glenmark Pharmaceuticals has been ranked number 1 in dermatologists’ prescriptions in the protective emollients category and for…
Glenmark partners with Pfizer to launch Abrocitinib in India
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively
Glenmark and Ichnos launch Ichnos Glenmark Innovation to accelerate new drug discovery in cancer…
The newly formed IGI features a pipeline of three innovative oncology molecules targeting multiple myeloma, acute myeloid leukemia…